Medical Condition News

RSS

Could Ozempic and Wegovy affect unborn babies?

They’re the blockbuster drugs transforming weight loss, helping millions of people to shed unwanted pounds.

10 Nov 2026

Qureight’s fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trial

Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, and Contineum Therapeutics, Inc. (Contineum), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that Qureight’s Fibr8™ quantitative imaging biomarker is being used as a secondary endpoint in Contineum’s PROPEL-IPF Phase 2 clinical trial examining the safety and efficacy of PIPE-791, Contineum’s lead drug candidate, in idiopathic pulmonary fibrosis (IPF) patients.

10 Nov 2026

European commission approves label expansion of Pepaxti to third-line treatment

Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announced that the European Commission (EC) has formally approved the Type II variation application for Pepaxti (melflufen).

From Oncopeptides AB (publ) 10 Nov 2026

A child's sex may change how early sugar intake relates to body fat

A longitudinal study of 130 mother-child pairs found that added sugar intake during pregnancy was more strongly associated with body fat in girls, whereas exposure during infancy was more strongly associated with adiposity in boys at age two. The findings, based largely on a smaller group of 42 children with usable body-composition scans, are preliminary and do not establish a causal relationship.

9 Nov 2026

DNA methylation patterns predict treatment response in MDS patients

DNA methylation patterns present at diagnosis could help predict which patients with myelodysplastic syndromes (MDS) will respond to azacitidine.

9 Nov 2026

UCLA study identifies lipid imbalance as pulmonary fibrosis trigger

A new UCLA Health study in mice has identified a new potential trigger for pulmonary fibrosis: lipid dysregulation (a fat imbalance) within alveolar macrophages.

9 Nov 2026

Australian-developed MND therapy advances to Phase 2 clinical trial

An Australian-developed therapy aimed at halting motor neurone disease progression and restoring function will advance to a national Phase 2 clinical trial.

9 Nov 2026

New treatment approach could help people with muscle-invasive bladder cancer live longer

A new treatment approach could help people with an aggressive form of bladder cancer live longer and reduce the chances of their cancer returning or progressing, particularly those who cannot receive standard chemotherapy, according to findings from a large international clinical trial co-led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center.

9 Nov 2026

Blocking complement factor B halts pancreatic cancer growth

Researchers have identified a promising new target in the treatment of pancreatic cancer. A new study in The American Journal of Pathology, published by Elsevier, demonstrates that blocking complement factor B (CFB), a pivotal enzyme in the alternative complement pathway, halts cancer growth and alters the tumor microenvironment.

9 Nov 2026

CAR-T cell therapy shows promising early results for stiff person syndrome

A multicenter clinical trial evaluating chimeric antigen receptor-T cell therapy (CAR-T cell therapy) for stiff person syndrome (SPS), a rare autoimmune neurologic disorder, has produced promising early results.

9 Nov 2026

VA grant funds implantable stimulator to improve the lives of disabled veterans

With a $3.1 million grant from the U.S. Department of Veterans Affairs (VA), a Case Western Reserve University (CWRU) researcher's quest to transform the quality of life of people living with spinal cord injuries will move closer to a clinical trial.

9 Nov 2026

Space station study tests colorectal cancer tumor avatars in microgravity

Researchers from Wake Forest Institute for Regenerative Medicine (WFIRM) are studying how microgravity affects how models of colorectal cancer cells respond to chemotherapy aboard the International Space Station.

9 Nov 2026

Liver transplants dramatically extend survival for alcohol-associated liver disease

People with alcohol-associated liver disease who received a liver transplant survived years longer than those who did not, but there are disparities in which patients receive a transplant.

9 Nov 2026

Monthly binge drinking increases advanced liver fibrosis risk in women

Women who consume four or more alcohol drinks on a single occasion once a month or more have increased odds of advanced liver fibrosis, a new study suggests.

9 Nov 2026

Blood biomarker tracks nerve damage from oxaliplatin-containing adjuvant chemotherapy

Oxaliplatin can cause numbness, tingling, and pain in the hands and feet, with consequences for mobility, work, and quality of life.

9 Nov 2026

Cannabis use increases mortality risk in alcohol-associated hepatitis patients

People with alcohol-associated hepatitis are more likely to die from the disease if they use cannabis. A large multinational study just published in Alcohol: Clinical and Experimental Research is the first to identify active substance use, particularly cannabis use, by patients as an independent predictor of death in patients with alcohol-associated hepatitis.

9 Nov 2026

Stanford study challenges long-held dogma on causes of concussions

Concussions - essentially mild traumatic brain injuries - are among the most common injuries sustained on athletic fields. In the U.S., an estimated 3.8 million sports-related concussions occur every year.

9 Nov 2026

New monoclonal antibody therapy significantly lowers patient triglyceride levels

A phase 2b clinical trial led by Mass General Brigham Heart and Vascular Institute researchers shows that a monoclonal antibody therapy called MAR001 can significantly reduce triglyceride levels within 12 weeks for patients with high triglyceride levels.

9 Nov 2026

Could a daily supplement keep blood vessels healthier as we age?

The study highlights a multi-compound nutritional supplement's potential to improve blood vessel function and lower blood pressure, aiding vascular health.

9 Nov 2026

Intravenous blood thinner improves heart recovery after cardiogenic shock

For heart attack patients who develop cardiogenic shock-the most serious complication of a heart attack-cangrelor, a potent intravenous blood thinner, resulted in better recovery of heart function when compared to oral antiplatelet therapy.

9 Nov 2026